RMTI Quote, Financials, Valuation and Earnings

Humacyte, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of -2325.37%. Rockwell Medical, Inc.'s return on equity of -17.16% beat Humacyte, Inc.'s return on equity of --.

Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 275.41%. On the other hand Humacyte, Inc. has an analysts' consensus of $7.86 which suggests that it could grow by 504.4%. Given that Humacyte, Inc. has higher upside potential than Rockwell Medical, Inc., analysts believe Humacyte, Inc. is more attractive than Rockwell Medical, Inc..

Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison Humacyte, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humacyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. Humacyte, Inc. pays out -- of its earnings as a dividend.

Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than Humacyte, Inc. quarterly revenues of $753K. Rockwell Medical, Inc.'s net income of -$1.8M is higher than Humacyte, Inc.'s net income of -$17.5M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while Humacyte, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.45x versus 118.43x for Humacyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of -255.85%. Rockwell Medical, Inc.'s return on equity of -17.16% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 275.41%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Rockwell Medical, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Rockwell Medical, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Rockwell Medical, Inc.'s net income of -$1.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.45x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Organon & Co. has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of 9.99%. Rockwell Medical, Inc.'s return on equity of -17.16% beat Organon & Co.'s return on equity of 79.63%.

Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 275.41%. On the other hand Organon & Co. has an analysts' consensus of $9.67 which suggests that it could grow by 32.97%. Given that Rockwell Medical, Inc. has higher upside potential than Organon & Co., analysts believe Rockwell Medical, Inc. is more attractive than Organon & Co..

Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison Organon & Co. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & Co. offers a yield of 4.68% to investors and pays a quarterly dividend of $0.02 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. Organon & Co. pays out 33.59% of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rockwell Medical, Inc. quarterly revenues are $15.9M, which are smaller than Organon & Co. quarterly revenues of $1.6B. Rockwell Medical, Inc.'s net income of -$1.8M is lower than Organon & Co.'s net income of $160M. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while Organon & Co.'s PE ratio is 3.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.45x versus 0.30x for Organon & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -11.01% compared to Rockwell Medical, Inc.'s net margin of --. Rockwell Medical, Inc.'s return on equity of -17.16% beat Palatin Technologies's return on equity of --.

Rockwell Medical, Inc. has a consensus price target of $3.75, signalling upside risk potential of 275.41%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Rockwell Medical, Inc., analysts believe Palatin Technologies is more attractive than Rockwell Medical, Inc..

Rockwell Medical, Inc. has a beta of 1.621, which suggesting that the stock is 62.123% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Rockwell Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Rockwell Medical, Inc. quarterly revenues are $15.9M, which are larger than Palatin Technologies quarterly revenues of --. Rockwell Medical, Inc.'s net income of -$1.8M is higher than Palatin Technologies's net income of --. Notably, Rockwell Medical, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical, Inc. is 0.45x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.